Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease

被引:42
作者
Cales, Paul [1 ,2 ]
Boursier, Jerome [1 ,2 ]
Chaigneau, Julien [2 ]
Laine, Fabrice [3 ,4 ]
Sandrini, Jeremy [5 ]
Michalak, Sophie [2 ,5 ]
Hubert, Isabelle [1 ,2 ]
Dib, Nina [1 ,2 ]
Oberti, Frederic [1 ,2 ]
Bertrais, Sandrine [2 ]
Hunault, Gilles [2 ]
Cavaro-Menard, Christine [6 ]
Gallois, Yves [7 ]
Deugnier, Yves [3 ,4 ]
Rousselet, Marie C. [2 ,5 ]
机构
[1] CHU Angers, Serv Hepatogastroenterol, F-49933 Angers 09, France
[2] Univ Angers, PRES UNAM, Lab HIFIH, Angers, France
[3] CHU, Hop Pontchaillou, INSERM, CIC 0203, Rennes, France
[4] CHU, Hop Pontchaillou, Serv Malad Foie, Rennes, France
[5] CHU Angers, Dept Pathol Cellulaire & Tissulaire, F-49933 Angers 09, France
[6] Univ Angers, PRES UNAM, Lab Ingn Syst Automatises, Angers, France
[7] CHU Angers, Lab Biochim & Biol Mol, F-49933 Angers 09, France
关键词
area of fibrosis; blood test; fractal dimension; image analysis; liver biopsy; liver fibrosis; metabolic syndrome NAFLD; LOGISTIC-REGRESSION; IMAGE-ANALYSIS; ACCURACY; MODELS; VARIABILITY; VALIDATION; BIOPSY; SYSTEM; NAFLD;
D O I
10.1111/j.1478-3231.2010.02314.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims: Our aim was to develop an accurate, non-invasive, blood-test-based method for identifying the main characteristics of liver fibrosis in non-alcoholic fatty liver disease (NAFLD). Methods: Fibrosis was staged according to NASH-CRN and Metavir systems in 226 patients with NAFLD. A fully automated algorithm measured the fractal dimension (FD) and the area of fibrosis (AOF). Independent predictors of diagnostic targets were determined using bootstrap methods. Results: (i) Development. Significant fibrosis defined by NASH-CRN F >= 2 was diagnosed by weight, glycaemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and prothrombin index [area under the receiver operating characteristic (AUROC) = 0.867]; significant fibrosis defined by Metavir F >= 2 was diagnosed by weight, age, glycaemia, AST, ALT, ferritin and platelets (FibroMeter AUROC = 0.941, P < 0.005). AOF was estimated by the combination of hyaluronic acid, glycaemia, AST, ALT, platelets and prothrombin index (R-a(2) = 0.530), while FD was estimated by hyaluronic acid, glycaemia, AST/ALT, weight and platelets (R-a(2) = 0.529). (ii) Evaluation. Although NASH-CRN was a better system for fibrosis staging, Metavir staging was a better reference for blood test. Thus, the patient rate with predictive values >= 90% by tests was 97.3% with Metavir reference vs. 66.5% with NASH-CRN reference (P < 10(-3)). FibroMeter showed a significantly higher AUROC than the NAFLD fibrosis score for significant fibrosis, but not for severe fibrosis or cirrhosis, with both staging systems. Relationships between fibrosis lesions were well reflected by blood tests, e. g., the correlation between histological area and FD of fibrosis (r(s) = 0.971, P < 10(-3)) was well reflected by the relationship between respective blood tests (rs = 0.852, P < 10(-3)). Conclusions: Different characteristics of fibrosis in NAFLD can be diagnosed and quantified by blood tests with excellent accuracy.
引用
收藏
页码:1346 / 1354
页数:9
相关论文
共 26 条
[1]   The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854
[2]   Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality [J].
Austin, PC ;
Tu, JV .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (11) :1138-1146
[3]  
BEDOSSA P, 1994, HEPATOLOGY, V20, P15
[4]   Using lowess to remove systematic trends over time in predictor variables prior to logistic regression with quantile categories [J].
Borkowf, CB ;
Albert, PS ;
Abnet, CC .
STATISTICS IN MEDICINE, 2003, 22 (09) :1477-1493
[5]   The STARD statement for reporting studies of diagnostic accuracy: Explanation and elaboration [J].
Bossuyt, PM ;
Reitsma, JB ;
Bruns, DE ;
Gatsonis, CA ;
Glasziou, PP ;
Irwig, LM ;
Moher, D ;
Rennie, D ;
de Vet, HCW ;
Lijmer, JG .
CLINICAL CHEMISTRY, 2003, 49 (01) :7-18
[6]   A novel panel of blood markers to assess the degree of liver fibrosis [J].
Calès, P ;
Oberti, F ;
Michalak, S ;
Hubert-Fouchard, I ;
Rousselet, MC ;
Konat, A ;
Gallois, Y ;
Ternisien, C ;
Chevailler, A ;
Lunel, F .
HEPATOLOGY, 2005, 42 (06) :1373-1381
[7]   Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C [J].
Cales, Paul ;
de Ledinghen, Victor ;
Halfon, Philippe ;
Bacq, Yannick ;
Leroy, Vincent ;
Boursier, Jerome ;
Foucher, Juliette ;
Bourliere, Marc ;
de Muret, Anne ;
Sturm, Nathalie ;
Hunault, Gilles ;
Oberti, Frederic .
LIVER INTERNATIONAL, 2008, 28 (10) :1352-1362
[8]   Comparison of blood tests for liver fibrosis specific or not to NAFLD [J].
Cales, Paul ;
Laine, Fabrice ;
Boursier, Jerome ;
Deugnier, Yves ;
Moal, Valerie ;
Oberti, Frederic ;
Hunault, Gilles ;
Rousselet, Marie Christine ;
Hubert, Isabelle ;
Laafi, Jihane ;
Ducluzeaux, Pierre Henri ;
Lunel, Francoise .
JOURNAL OF HEPATOLOGY, 2009, 50 (01) :165-173
[9]   ESTIMATION OF THE COEFFICIENT OF VARIATION FROM LABORATORY ANALYSIS OF SPLIT SPECIMENS FOR QUALITY-CONTROL IN CLINICAL-TRIALS [J].
CONNETT, JE ;
LEE, WW .
CONTROLLED CLINICAL TRIALS, 1990, 11 (01) :24-36
[10]   Long-term follow-up of patients with NAFLD and elevated liver enzymes [J].
Ekstedt, Mattias ;
Franzen, Lennart E. ;
Mathiesen, Ulrik L. ;
Thorelius, Lars ;
Holmqvist, Marika ;
Bodemar, Goran ;
Kechagias, Stergios .
HEPATOLOGY, 2006, 44 (04) :865-873